STROBE Statement—checklist of items that should be included in reports of observational studies

Section/item	Item No	Recommendation	Reported on Page Number/Line Number	Reported on Section/Paragraph
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	Page1/line 5	Title
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	Page2/line 1-26	Abstract/Paragraph1-4
Introduction				
Background/ rationale	2	Explain the scientific background and rationale for the investigation being reported	Page3/line 1-34; page4/line 1-6	Introduction/Paragraph1-4
Objectives	3	State specific objectives, including any prespecified hypotheses	Page4/line 11-14	Introduction/Paragraph4
Methods				
Study design	4	Present key elements of study design early in the paper	Page 4/line 20	Patient selection /Paragraph 1
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	Page 4/line 20-28	Patient selection /Paragraph 1
Participants	6	(a) **Cohort study**—Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up	Page 4/line 28-34	Patient selection /Paragraph 1
		(b) **Cohort study**—For matched studies, give matching criteria and number of exposed and unexposed	Page 5/line 7-16	Statistical analysis /Paragraph 2
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	N/A	No variables need to be defined.
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	N/A	No variables were needed to be measured, and all data were extracted from the database.
Bias	9	Describe any efforts to address potential sources of bias	Page 4/line 33	Patient selection /Paragraph 1
Study size	10	Explain how the study size was arrived at	Page 4/line 25-26	Patient selection /Paragraph 1
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	N/A	All variables in this study were non-continuous-type variables

Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	Page5/line 4-25	Statistical analysis /Paragraph 1-3
		(b) Describe any methods used to examine subgroups and interactions	Page 5/line 24-25	Statistical analysis /Paragraph 3
		(c) Explain how missing data were addressed	Page 4/line 33	Patient selection /Paragraph 1
		(d) **Cohort study**—If applicable, explain how loss to follow-up was addressed	Page 4/line 32-33	Statistical analysis /Paragraph 1
		(e) Describe any sensitivity analyses	N/A	A sensitivity analysis was not performed in this study
Results				
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	Page 4/line 28-34; Page 21/line 1-7	Patient selection /Paragraph 1; figure 1
		(b) Give reasons for non-participation at each stage	Page 4/line 28-34; Page 21/line 1-7	Patient selection /Paragraph 1; figure 1
		(c) Consider use of a flow diagram	Page 21/line 1-7	Figure 1
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	Page15/line 1-4; Page16/line 1-5;	Table1;table 2
		(b) Indicate number of participants with missing data for each variable of interest	Page 4/line 33	Patient selection /Paragraph 1
		(c) **Cohort study**—Summarise follow-up time (eg, average and total amount)	Page 5/line 29-34	Baseline characteristics /Paragraph 1
Outcome data	15*	**Cohort study**—Report numbers of outcome events or summary measures over time	Page22/line 4-9;	Figure 4
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	Page 17-18/ /line 1-5; Page 19-20/ /line 1-5;	Table 3;table 4
		(b) Report category boundaries when continuous variables were categorized	N/A	All the study variables in this study were non-continuous-type variables
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	N/A	AAE was not calculated
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	Page6;7/ line29-34;1-16 Page23-25/ line 1-7;	Result/paragraph 5-7; Figure 5-7
Discussion				
Key results	18	Summarise key results with reference to study objectives	Page 9/ line28-30	Conclusions/Paragraph 1
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	Page 9/line 15-25	Discussion/ Paragraph 5

Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	Page 7;8;9/line 27-34;1-34;1-7	conclusion/ Paragraph 1-3
Generalisability	21	Discuss the generalisability (external validity) of the study results	Page 9/line 8-14	Discussion/ Paragraph 4
Other information				
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	Page 9/line 33	Funding/Paragraph 1

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.strobe-statement.org.

Article Information: https://dx.doi.org/10.21037/jgo-21-815
*As the checklist was provided upon initial submission, the page number/line number reported may be changed due to copyediting and may not be referable in the published version. In this case, the section/paragraph may be used as an alternative reference.